# US 2025/0144198 A1 · Next generation vaccines comprising antigenic libraries and methods of making and using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144198 A1
- Document ID: US20250144198A1
- Status: Published application
- Kind: A1
- Application number: 18/684,346
- Filed: 2022-08-16
- Published: 2025-05-08
- Earliest claimed: 2021-08-16
- Assignees: Duke University
- Applicants: Duke University
- Inventors: Nicholas HEATON; Zhaochen LUO
- Web page: https://patentgrep.com/patent/US20250144198A1

## CPC

- A61K 39/12: Viral antigens
- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61P 31/16: for influenza or rhinoviruses
- A61P 37/04: Immunostimulants
- C07K 14/005: from viruses
- C12N 15/1058: {Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms}
- G01N 33/6845: {Methods of identifying protein-protein interactions in protein mixtures}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N 2760/16022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16071: Demonstrated in vivo effect
- C12N 2760/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C40B 40/02: Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
- C40B 40/08: Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)

## Abstract

The present invention provides protein libraries comprising variants of an antigenic viral protein that each have a different set of mutations at one or more hypervariable sites. Nucleic acid and vector libraries encoding the protein libraries, vaccines comprising the libraries, and methods of inducing an immune response against the antigenic viral protein are also provided.

## Claims

### Claim 1

A protein library comprising variants of an antigenic viral protein, wherein each variant of the antigenic viral protein comprises a different set of mutations at one or more hypervariable sites in the antigenic viral protein.

### Claim 2 (depends on 1)

The protein library of claim 1, wherein the protein library comprises at least 1×104 variants of the antigenic viral protein.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The protein library of any one of claim 1, wherein the antigenic viral protein is from influenza virus, human immunodeficiency virus (HIV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), hepatitis C virus (HCV), respiratory syncytial virus (RSV), or human cytomegalovirus (CMV).

### Claim 5 (depends on 4)

The protein library of claim 4, wherein the antigenic viral protein is hemagglutinin (HA).

### Claim 6 (depends on 5)

The protein library of claim 5, wherein the antigenic viral protein is a group 1 influenza A HA, a group 2 influenza A HA, or an influenza B HA.

### Claim 7 (depends on 6)

The protein library of claim 6, wherein the one or more hypervariable sites are in:
a) a region of HA 1 selected from Cb, Sa, Ca2, Ca1, and Sb, as shown in FIG. 11; or
b) a region of HA 3 selected from A, B, C, D, and E, as shown in FIG. 11.

### Claim 8 (depends on 7)

The protein library of claim 7, wherein the one or more hypervariable sites are:
a) selected from positions Sb 192, Sb 193, Sb 196, and Sb 198; or
b) in a region of B HA selected from the 120 loop, 150 loop, 160 loop, and 190 helix, as shown in FIG. 11.

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11 (depends on 1)

A nucleic acid library encoding the protein library of claim 1, wherein each nucleic acid in the nucleic acid library comprising a sequence encoding one of the variants of the antigenic viral protein of the protein library.

### Claim 12 (depends on 11)

The nucleic acid library of claim 11, wherein each nucleic acid in the nucleic acid library further comprises a promoter operably linked to the sequence encoding one of the variants of the antigenic viral protein.

### Claim 13 (depends on 11)

A vector library comprising the nucleic acid library of claim 11, wherein each vector in the vector library comprises one of the nucleic acids of the nucleic acid library.

### Claim 14

(canceled)

### Claim 15 (depends on 11)

A virus library comprising the nucleic acid library of claim 11, wherein each virus in the virus library comprises one of the nucleic acids of the nucleic acid library.

### Claim 16 (depends on 15)

The virus library of claim 15, wherein the virus is selected from the group consisting of influenza virus, HIV, SARS-CoV-2, HCV, RSV, and CMV.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

A vaccine comprising the protein library of claim 1 and an adjuvant.

### Claim 19 (depends on 1)

A method of inducing an immune response against the antigenic viral protein in a subject, the method comprising: administering to the subject the protein library of claim 1.

### Claim 20 (depends on 19)

The method of claim 19, wherein the immune response against the variants of the antigenic viral protein is altered as compared to the immune response against a wild-type antigenic viral protein.

### Claim 21 (depends on 20)

The method of claim 20, wherein a greater number of antibodies recognizing distinct epitopes of the antigenic viral protein are generated in response to the variants of the antigenic viral protein as compared to in response to vaccination with a wild-type antigenic viral protein.

### Claim 22 (depends on 20)

The method of claim 20, wherein a greater proportion of antibodies are generated against conserved sites as compared to hypervariable sites within the antigenic viral protein in response to the variants of the antigenic viral protein as compared to in response to vaccination with a wild-type antigenic viral protein.

### Claim 23 (depends on 22)

The method of claim 22, wherein the immune response is protective against a highly drifted strain of the virus.

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26 (depends on 13)

A method of generating the vector library of claim 13, the method comprising:
a) performing saturation mutagenesis on nucleic acids encoding the antigenic viral protein at one or more hypervariable sites of the antigenic viral protein to obtain mutated nucleic acids;
b) cloning the mutated nucleic acids into viral vectors;
c) packaging the viral vectors into viruses;
d) transducing the viral vectors into cells by infecting the cells with the viruses;
e) identifying infected cells that express the antigenic viral protein;
f) cloning the mutated nucleic acids encoding variants of the antigenic viral protein found in the infected cells into an expression vector to generate the vector library.

### Claim 27

A method of performing saturation mutagenesis on a plurality of target sites within a DNA sequence of interest, the method comprising:
a) designing a plurality of overlapping primers that are complementary to sequences flanking the target sites and comprise mutations at the target sites;
b) performing a recombination reaction in which the primers are annealed to each other to form a set of recombinant primers that each comprise a different set of mutations at the target sites;
c) extending the recombinant primers using a DNA polymerase to form full-length sequences that span the target sites;
d) amplifying the full-length sequences to form an amplification reaction product;
e) purifying the amplification reaction product; and
f) cloning the amplification reaction product into an appropriate vector.

### Claim 28 (depends on 27)

The method of claim 27, wherein the mutations comprise NNK for forward primers and/or MNN for reverse primers.

### Claim 29

(canceled)
